The US government will not move psilocybin off its most restricted drug category (Schedule I — meaning 'no accepted medical use, high abuse potential') within the next 18 months. This matters because Schedule I status makes research harder, keeps criminal penalties in place, and means no legal medical use at the federal level.
Diversion risk hasn't changed. Medical approval creates a narrow lane, not descheduling. Communities pay when we normalize too fast. Enforcement priorities hold.